MGMT and lymphopenia: In another study, lymphopenia at baseline was detected in 24.3% (out of n=562) of elderly patients with glioblastoma (≥65 years) and was associated with worse overall survival (HR 1.30; 95% CI 1.05–1.62; p=0.02), regardless of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (50).